Want to know if this job is worth applying to?
Remote
Remote only
Definium Therapeutics is a late-stage clinical biopharmaceutical company and our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale.
Our lead product candidate, lysergide tartrate (our proprietary orally disintegrating tablet form of lysergide (LSD) D-tartrate), represents a highly differentiated, potential best-in-class opportunity for patients suffering from generalized anxiety, major depressive disorder, and posttraumatic stress disorder. Our early stage pipeline includes DT402, the R-enantiomer of MDMA and is under development to target the core symptoms of autism spectrum disorder (ASD), specifically addressing social communication challenges.
Guided by the recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.
Together we are moving psychiatry forward—beyond better, into a boundless future. Join us!
The Senior Director, National Accounts implements Definium’s market access strategy across assigned commercial payer and PBM accounts and develops account-specific recommendations to support patient access and reimbursement. This role focuses on commercial national accounts and excludes Medicaid and other government accounts.
Primary Responsibilities
Primary Customers
Required Qualifications
Compliance and PIE-Aligned Communications
Payer communications, including appropriate pre-approval information exchange and healthcare economic information, will be conducted in alignment with approved company materials, Medical/Legal/Regulatory review processes, applicable FDA guidance, PIE guidelines, and company compliance policies. This role will partner closely with internal stakeholders to ensure payer planning discussions are accurate, consistent, and appropriately aligned with approved access, value, and launch readiness objectives.
The starting base pay range for this position is $220,000.00 - $280,000.00. Compensation will be determined based on several factors including, but not limited to, skill set, years of experience, and the employee’s geographic location.
Employees in this role may be entitled to additional compensation, including bonus and equity. Benefits information is listed on our Jobs Page. The Company provides competitive benefits to employees including:
